Review for AstraZeneca

4 January 2007
More news

04 January 2007

Pharmaceutical company AstraZeneca plans to improve its supply chain arrangements for distributing medicines in the UK.

In a statement the company said it had undertaken an independent strategic review of its operations: "This has highlighted that there are a number of opportunities for AstraZeneca to improve the supply chain for our medicines in the UK. As a result of this initiative, we have approached a number of organisations who are capable of working with us for the supply of our medicines in the UK."

A spokeswoman for the firm told SM it was not in a position to discuss the detail of the new supply chain model. But the firm has denied reports that it aims to copy US rival Pfizer by distributing all its products through a single organisation.

Independent pharmacies, wholesalers and MPs have protested over a deal between Pfizer and British-based Alliance Boots. Labour MP David Taylor tabled an early day motion in December to express concern at the proposed changes, due to begin this spring.

It says it is an "unacceptable risk" to leave the distribution of drugs with one company and details how Pfizer ran out of its treatment for high blood pressure last year. The motion has so far been signed by 45 MPs.


GBP60000 - GBP75000 per annum +
1st Executive
West London
GBP30000 - GBP35000 per annum + benefits
1st Executive
CIPS Knowledge
Find out more with CIPS Knowledge:
  • best practice insights
  • guidance
  • tools and templates